Enterprise Value
-481.1K
Cash
15.39M
Avg Qtr Burn
-15.35M
Short % of Float
0.51%
Insider Ownership
25.54%
Institutional Own.
9.30%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MB-107 Details X-Linked severe combined immunodeficiency | Phase 2 Initiation | |
MB-207 Details X-Linked severe combined immunodeficiency, Myelofibrosis | Phase 2 Initiation | |
MB-110 (LV-RAG1) Details Severe combined immunodeficiency due to complete RAG1/2 deficiency | Phase 1/2 Data readout | |
MB-106 (CD20) (Mustang Multicenter) Details Non-Hodgkin lymphoma, Cancer, Lymphoma, Chronic lymphocytic leukemia | Phase 1/2 Data readout | |
MB-106 (CD20) (Fred Hutch) Details Non-Hodgkin lymphoma, Lymphoma, Chronic lymphocytic leukemia, Multiple sclerosis, Epstein-Barr virus, Cancer, Waldenstrom macroglobulinemia | Phase 1/2 Update | |
MB-105 (PSCA) Details Prostate cancer, Multiple myeloma, Cancer | Phase 1 Data readout | |
MB-104 Details Multiple myeloma, Solid tumor/s, Cancer | Phase 1 Data readout | |
MB-103 (HER2) Details Glioblastoma, Metastatic breast cancer to brain, Cancer | Phase 1 Data readout | |
MB-101 (IL-13Ra2) + MB-108 Details Glioblastoma, Ependymoma, Medulloblastoma, Leptomeningeal brain tumors | Phase 1 Update | |
MB-102 (CD123) Details High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer | Failed Discontinued |